DVAX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DVAX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Dynavax Technologies's Forward PE Ratio for today is 39.54.
Dynavax Technologies's PE Ratio without NRI for today is 76.67.
Dynavax Technologies's PE Ratio (TTM) for today is 76.67.
The historical data trend for Dynavax Technologies's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavax Technologies Annual Data | |||||||
Trend | 2021-12 | 2023-12 | 2024-12 | ||||
Forward PE Ratio | 58.48 | 23.31 | 51.18 |
Dynavax Technologies Quarterly Data | ||||||||||||
2016-03 | 2021-03 | 2021-06 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2023-09 | 2023-12 | 2024-03 | 2024-09 | 2024-12 | |
Forward PE Ratio | 64.94 | 17.83 | 34.13 | 99.01 | 58.48 | 10.21 | 10.28 | 212.77 | 23.31 | 416.67 | 54.95 | 51.18 |
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Dynavax Technologies (NAS:DVAX) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Thank you for viewing the detailed overview of Dynavax Technologies's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Francis Cano | director | 11 ACORN LANE, LOS ALTOS CA 94022 |
Justin Burgess | officer: Principal Accounting Officer | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608 |
Robert Janssen | officer: Chief Medical Officer and VP | C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
David F Novack | officer: Senior Vice President | 39 YORKSHIRE DR, OAKLAND CA 94618 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Ryan Spencer | officer: Co-President and Senior VP | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753 |
Elaine D Sun | director | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Scott Dunseth Myers | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Kelly Macdonald | officer: SVP and CFO | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Peter R. Paradiso | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608 |
Julia Marie Eastland | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Brent Macgregor | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608 |
Peggy V Phillips | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
Robert Coffman | officer: Chief Science Officer and VP | C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710 |
Michael S Ostrach | officer: VP, CBO, and General Counsel | 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063 |
From GuruFocus
By GuruFocus News • 11-08-2024
By PRNewswire • 01-13-2025
By GuruFocus Research • 09-24-2024
By GuruFocus News • 10-28-2024
By GuruFocus News • 10-25-2024
By PRNewswire • 11-11-2024
By GuruFocus News • 11-08-2024
By GuruFocus News • 10-09-2024
By GuruFocus News • 02-15-2025
By PRNewswire • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.